The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH/ISH 2016 | How to manage infections in CLL patients on idelalisib
Andrew Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, New York, NY discusses the management of infections when treating chronic lymphocytic leukemia (CLL) patients with idelalisib. For opportunistic infections, it is important to provide prophylaxis when it comes to pneumocystis. Dr Zelenetz also discusses enhanced neutropenia and the use of dapsone. For cytomegalovirus (CMV), the key is monitoring.
Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.
